阿立哌唑与利培酮治疗精神分裂症58例对照研究

Aripiprazole and risperidone in the treatment of schizophrenia-control study

目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法:将58例精神分裂症患者随机分为两组,每组29例,观察8周。于治疗前及治疗2、4、8周末采用阳性与阴性症状量表及不良反应量表评定临床疗效和不良反应。结果:治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降(P<0.05或P<0.01),同期两组间评分差异均无显著性(P>0.05);治疗8周末,阿立哌唑组显效率75.87%,有效率89.66%,利培酮组分别为75.86%,93.10%,两组差异无显著性(P>0.05)。两组不良反应均轻微,但阿立哌唑组静坐不能、体重增加及月经紊乱/泌乳发生率均显著低于利培酮组(P<0.05)。而口干发生率显著高于对照组(P<0.05)。结论:阿立哌唑与利培酮治疗精神分裂症疗效均显著,临床疗效及安全性有一定异同,临床可根据个体差异选择药物。

Objective：To compare aripiprazole and risperidone in the treatment of schizophrenia and safety. Methods：58 cases of pain in patients with schizophrenia were randomly divided into two groups of 29 cases, 8 weeks. Before treatment and at 2 weeks, 4 weeks, 8 weeks patients using positive and negative symptoms and side effects rating scale scale clinical efficacy and adverse reactions. Results： After treatment, the Positive and Negative Syndrome Scale total score and factor scores than those before treatment significantly decreased （ P 〈 0.05 or P 〈 0. 01 ）, that the score difference between the two groups are of utmost significant （ P 〉 0.05） ; treatment 8 weeks, aripiprazole group was 75.87% efficiency, efficiency 89.66% , risperidone group were 75.86% , 93.10% , the difference was not significant （P 〉0.05）. Two sets of adverse reactions were mild, but the aripiprazole group akathisia, weight gain and menstrual disorders / lactation were significantly lower than the risperidone group （ P 〈 0.05 ）. While the dry mouth incidence was significantly higher （ P 〈 0.05 ）. Conclusions ： Aripiprazole and risperidone in the treatment of schizophrenia, clinicalefficacy and safety of certain similarities and differences, the clinical drug of choice based on individual differences.